• Users Online: 102
  • Print this page
  • Email this page

  About Us

 About the Society

HealthCare Global Enterprises Ltd, (HCG) are focused on cancer care with its flagship hospital in Bangalore, India and a wide network of hospitals spread across India, Africa and South East Asia. With a strong belief of personalized care and value-based medicine, HCG attempts to bring to one platform, experience and evidence for precision oncology through this Journal.

  About the Journal

The Journal of Precision Oncology is the official semi-annual Publication of Healthcare Global Enterprises Limited. and is based  on the recognition  that precision medicine is now a reality  in the field of oncology . Current understanding of cancer provides opportunities to understand each cancer, and patient  as unique and to tailor make care strategies that cater to this uniqueness while adhering to evidence based practices. This journal is available online as well as in print format.

Abstracting and Indexing Information

The journal is registered with the following abstracting partners:
Baidu Scholar, CNKI (China National Knowledge Infrastructure), EBSCO Publishing's Electronic Databases, Ex Libris Primo Central, Google Scholar, Hinari, Infotrieve, Netherlands ISSN centre, ProQuest, TDNet, Wanfang Data

Journal Ethics

Wolters Kluwer and Journal/Association are committed to meeting and upholding standards of ethical behavior at all stages of the publication process. We follow closely the industry associations, such as the Committee on Publication Ethics (COPE), International Committee of Medical Journal Editors (ICMJE) and World Association of Medical Editors (WAME), that set standards and provide guidelines for best practices in order to meet these requirements. For a summary of our specific policies regarding duplicate publication, conflicts of interest, patient consent, etc., please visit www.Medknow.com/EthicalGuidelines.asp

Open Access Publication and Creative Commons Licensing

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Digital Archiving

Wolters Kluwer Medknow provides for long-term digital preservation through two primary partnerships, Portico and CLOCKSS.

Portico is a leading digital preservation service worldwide. The content is preserved as an archival version and is not publically accessible via Portico, but is provided when required under specific conditions, such as discontinuation of the collection or catastrophic failure of the website.

CLOCKSS will enable any library to maintain their own archive of content from Wolters Kluwer Medknow and other publishers, with minimal technical effort and using cheaply available hardware.

Ahead of Print policy

Articles published online under the Ahead of Print model are considered published and can be cited and quoted using the DOI as the reference source. Wolters Kluwer Medknow has a policy that changes will not be made after publication of an article without following accepted procedures for making corrections to the scientific record.


While advertisements are crucial to this journal to be able to keep all content free for everyone, ethical considerations are in place to ensure the integrity of the journal and its content:

  • "Pop-up" and "banner" ads appear on a random, rotating basis. The advertiser has no control or input over the pages where their ads appear.
  • The Editorial Board has full and final approval over the content of all advertisements.
  • Advertisers will never be shown any manuscripts or other content prior to publication.

  Scope of the journal

The Journal encourages submissions that highlight how oncology care is becoming more personalized and is modified based on the specific attributes of the tumor and the patients, while retaining strong evidence and rationale. Submissions could include basic, translational, transitional, and clinical research studies. Case studies, structured reviews, and open editorials that are enablers of precision oncology are also invited. Outcome driven studies will be given preference.

    Medknow Publications   Top
Editorial board